Evidence map›Paper›PMID 33076457›Full record

ArticleCancers2020

Validating fPSA Glycoprofile as a Prostate Cancer Biomarker to Avoid Unnecessary Biopsies and Re-Biopsies.

Tomas Bertok, Eduard Jane, Aniko Bertokova, Lenka Lorencova, Peter Zvara, Bozena Smolkova, Radek Kucera, Helmut Klocker, Jan Tkac

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Tomas BertokDepartment of Glycobiotechnology, Institute of Chemistry, Slovak Academy of Sciences, Dubravska cesta 9, 845 38 Bratislava, Slovakia.ORCID 0000-0001-7075-2687
Eduard JaneDepartment of Glycobiotechnology, Institute of Chemistry, Slovak Academy of Sciences, Dubravska cesta 9, 845 38 Bratislava, Slovakia.
Aniko BertokovaDepartment of Glycobiotechnology, Institute of Chemistry, Slovak Academy of Sciences, Dubravska cesta 9, 845 38 Bratislava, Slovakia.
Lenka LorencovaDepartment of Glycobiotechnology, Institute of Chemistry, Slovak Academy of Sciences, Dubravska cesta 9, 845 38 Bratislava, Slovakia.
Peter ZvaraDepartment of Clinical Research, University of Southern Denmark, J. B. Winsløws Vej 23, 5000 Odense C, Denmark.
Bozena SmolkovaDepartment of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Dubravska cesta 9, 845 04 Bratislava, Slovakia.ORCID 0000-0002-4906-5652
Radek KuceraDepartment of Immunochemistry Diagnostics, University Hospital in Pilsen, E. Benese 1128/13, 301 00 Pilsen, Czech Republic.ORCID 0000-0002-2739-2302
Helmut KlockerDepartment of Urology, Medical University Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria.ORCID 0000-0001-7732-9443
Jan TkacDepartment of Glycobiotechnology, Institute of Chemistry, Slovak Academy of Sciences, Dubravska cesta 9, 845 38 Bratislava, Slovakia.ORCID 0000-0002-0765-7262
Institute of Chemistry of the Slovak Academy of Sciences · SKInnsbruck Medical University · ATSlovak Academy of Sciences · SKUniversity of Southern Denmark · DK

Funding

Agentúra na Podporu Výskumu a Vývoja APVV 17-0300H2020 European Research Council . 825586
6 · The paper itself

Abstract

backgroundTo compare the clinical performance of a new PCa serum biomarker based on fPSA glycoprofiling to fPSA% and PHI.

methodsSerum samples from men who underwent prostate biopsy due to increased PSA were used. A comparison between two equal groups (with histologically confirmed PCa or benign, non-cancer condition) was used for the clinical validation of a new glycan-based PCa oncomarker. SPSS and R software packages were used for the multiparametric analyses of the receiver operating curve (ROC) and for genetic algorithm metaheuristics.

resultsWhen comparing the non-cancer and PCa cohorts, the combination of four fPSA glycoforms with two clinical parameters (PGI, prostate glycan index (PGI)) showed an area under receiver operating curve (AUC) value of 0.821 (95% CI 0.754-0.890). AUC values were 0.517 for PSA, 0.683 for fPSA%, and 0.737 for PHI. A glycan analysis was also applied to discriminate low-grade tumors (GS = 6) from significant tumors (GS ≥ 7).

conclusionsCompared to PSA on its own, or fPSA% and the PHI, PGI showed improved discrimination between presence and absence of PCa and in predicting clinically significant PCa. In addition, the use of PGI would help practitioners avoid 63.5% of unnecessary biopsies, while the use of fPSA% and PHI would help avoid 17.5% and 33.3% of biopsies, respectively, while missing four significant tumors (9.5%).

Indexed as

biomarkersdiagnosticsfPSAglycansprognosticsprostate cancer

Identifiers

PMID33076457
PMCPMC7602627
OpenAlexW3092872523

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.